WuXi Biologics, part of WuXi AppTec, a contract service provider, and Pall Corporation, a provider of filtration, separation and purification products and services, have established a joint laboratory to develop full continuous processing for the manufacturing of monoclonal antibodies (mAb).

The three-year project started with the continuous operation of individual processes and will gradually be expanded to downstream processing development and production.

The joint laboratory, constructed with Pall Life Sciences’ Cadence Integrated Continuous Bioprocess System and integrated with its single-use technology platform, is designed to switch between processes and avoid cross-contamination.

With this joint laboratory, WuXi Biologics said it plans to soon expand its continuous process scale to 500 liters and reduce mAb manufacturing costs to $30-$50 per gram, and then scale up to 1,000 liters and further reduce costs to less than $15 per gram.

Source: WuXi Biologics